16.6.2026 07:00:01 CEST | Thor Medical ASA | Ikke-informasjonspliktige
pressemeldinger

Thor Medical ASA today announced that Dr. Alf Bjørseth will retire from his
position as EVP Business Development effective June 30, 2026.

Dr. Bjørseth previously served as CEO of Thor Medical and has been instrumental
in the development of the company. At 84 years of age, he has decided to step
down from his executive position.

"Alf has played an important role in the development of Thor Medical. I would
like to thank him for his commitment to the company. Knowing Alf, I'm sure he
will stay engaged and follow the development as we continue our further
progress," said CEO of Thor Medical, Jasper C. Kurth. 



For further information, please contact:

Thor Medical ASA

Mathias Nilsen Reierth, Head of Communications and Corporate Affairs

+47 988 05 724, mathias.reierth@thormedical.com

ABOUT THOR MEDICAL ASA

Thor Medical is an emerging supplier of alpha particle emitters produced from
naturally occurring thorium, a key component of next-generation targeted cancer
treatment. Its proprietary production process requires no irradiation or use of
nuclear reactors, and provides a reliable, environmentally friendly and
cost-efficient supply of alpha emitters to the radiopharmaceutical industry.
Guided by its vision to become a world-leading enabler for targeted cancer
therapies, Thor Medical is committed to improving millions of lives by fueling
next-generation cancer therapies with high-purity isotopes. Thor Medical is
headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange under the
ticker symbol TRMED. For more information, visit www.thormedical.com -
http://www.thormedical.com - https://www.thormedical.com.

VEDLEGG

Last ned som PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18952640/12145/Last%20ned%20som%2
0PDF.pdf
-files/17848634/18952640/12145/Last%20ned%20som%2\
0PDF.pdf\